Table 3. Prognostic factors for disease-free survival.
Unadjusted
a
|
Cox regression, full model
b
|
Cox regression, variable selection
c
|
||||
---|---|---|---|---|---|---|
HR (95% CI) | P d | HR (95% CI) | P d | HR (95% CI) | P d | |
C-stage | ||||||
C-stage 0 | Reference | <0.001 | Reference | <0.001 | Reference | <0.001 |
C-stage I | 2.63 (1.89–3.65) | 2.17 (1.51–3.10) | 2.08 (1.48–2.94) | |||
Age (years) | 1.05 (1.03–1.07) | <0.001 | 1.04 (1.03–1.06) | <0.001 | 1.04 (1.03–1.06) | <0.001 |
Gender | ||||||
Male | Reference | 0.44 | Reference | 0.435 | — | |
Female | 0.88 (0.63–1.23) | 0.89 (0.62–1.27) | ||||
BMI (kg m−2) | 0.95 (0.91–0.99) | 0.008 | 0.96 (0.92–1.00) | 0.037 | 0.96 (0.92–1.00) | 0.048 |
ASA stage | ||||||
II | Reference | 0.002 | Reference | 0.54 | — | |
III/IV | 1.74 (1.23–2.45) | 0.92 (0.59–1.41) | ||||
Cardiovascular disease | ||||||
No | Reference | 0.006 | Reference | 0.605 | — | |
Yes | 1.75 (1.20–2.56) | 1.07 (0.67–1.72) | ||||
Chronic obstructive pulmonary disease | ||||||
No | Reference | 0.002 | Reference | 0.191 | — | |
Yes | 2.12 (1.36–3.32) | 1.29 (0.78–2.12) | ||||
Chronic kidney disease | ||||||
No | Reference | 0.02 | Reference | 0.137 | — | |
Yes | 2.68 (1.27–5.67) | 1.83 (0.80–4.19) | ||||
AJCC stage | ||||||
I | Reference | Reference | 0 | Reference | <0.001 | |
II | 1.49 (0.97–2.28) | 1.18 (0.75–1.86) | 1.26 (0.81–1.96) | |||
III | 2.56 (1.74–3.79) | 2.15 (1.40–3.31) | 2.20 (1.48–3.28) | |||
Distance to anal verge | ||||||
>10 cm | Reference | 0 | Reference | 0.047 | Reference | 0.001 |
>5–10 cm | 1.28 (0.82–2.00) | 1.86 (1.07–3.23) | 1.39 (0.88–2.19) | |||
0–5 cm | 2.22 (1.43–3.46) | 1.29 (0.80–2.08) | 2.19 (1.39–3.45) | |||
Neoadjuvant therapy | ||||||
No | Reference | 0.746 | Reference | 0.258 | — | |
Yes | 0.98 (0.71–1.36) | 1.22 (0.83–1.80) | ||||
Operation | ||||||
Anterior resection | Reference | 0.003 | Reference | 0.45 | — | |
Abd. perineal excision | 2.00 (1.29–3.11) | 1.16 (0.69–1.94) | ||||
Operation time (hours) | 1.05 (0.92–1.19) | 0.437 | 1.03 (0.90–1.18) | 0.551 | — | |
Adjuvant therapy | ||||||
No | Reference | 0.589 | Reference | 0.587 | — | |
Yes | 0.93 (0.66–1.30) | 1.07 (0.71–1.60) |
Abbreviations: AJCC=American Joint Committee on Cancer; ASA=American Society of Anesthesiologists.
Hazard ratios (HR) with 95% confidence intervals resulting from:
Univariate, Cox proportional hazards regression analysis for disease-free survival;
Independent, full model Cox proportional hazards regression analysis for disease-free survival;
Independent, backward variable selection Cox proportional hazards regression analysis for disease-free survival (confirmed by forward variable selection with identical results);
P-values from likelihood ratio tests.